Clonal T cell populations with idiotype specificity are present to CD3 stimulation which boosts antitumour effector mechin the peripheral blood of a proportion of patients with multiple anisms. 15 It has also been shown that increased numbers of vations provide evidence for the existence of idiotype-reactive
The presence of T cell receptor ␤ gene rearrangements has In this study we have evaluated the prognostic significance of rearrangements of the T cell receptor ␤ gene detected in Introduction the peripheral blood of 83 patients with myeloma. The incidence of T cell receptor ␤ gene rearrangements has been Myeloma cells express idiotypic immunoglobulin-derived determined together with the median survival. The prognostic molecules on their cell surface which may be regarded as significance during the course of the disease has been evalutumour-specific antigens. In murine myeloma models, T cells ated in longitudinal studies. In addition, we have demonwith a specificity for these antigens have been detected [1] [2] [3] and strated that the presence of idiotype-reactive T cells correlates an antitumour response involving both T cell cytotoxicity and with the presence of rearrangements in the T cell receptor ␤ protective immunity has been demonstrated. This response gene. can be enhanced by stimulation with recombinant IL-2. 4 In humans, the evidence that T cells play a role in the immunoregulation of myeloma is not as conclusive as that in murine Materials and methods models but idiotype-reactive T cells have been detected by several groups in both CD4 and CD8 subsets from patients with myeloma. [5] [6] [7] [8] [9] By using monoclonal antibodies against
Patients studied specific V␤ families of T cell receptors it has been shown that oligoclonal T cell populations exist and are either from a rare After informed consent, 119 peripheral blood samples were CD4 + CD28 − T cell subset associated with granular morcollected from 83 patients with myeloma presenting to our phology or are CD8 + CD45RA + CD11b + T cells. 10 In addition, clinic. Samples were collected at all stages of the disease patients with myeloma can have an altered CD4:CD8 ratio including presentation (n = 35), plateau/stable phase (n = 39) which is related to a decrease in naive CD4 cells in advanced and progressive disease (n = 45). Patients were treated accordstages of the disease, 11, 12 an increased number of large granuing to the ALSG myeloma trial protocol which involved multilar lymphocytes and activated T cells 10, 13, 14 and a sensitivity agent therapy (prednisone, cyclophosphamide, doxorubicin and bis-chloronitrosourea) plus or minus alpha-interferon.
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Patients over 70 years were treated with melphalan and prednisone.
Purification and biotinylation of immunoglobulin electrophoresed in 0.8% agarose gels and transferred to Hybond nylon filters (Amersham International, Little Chalfont, fragments UK). Hybridisation was performed at 65°C overnight in a Hybaid oven according to established procedures. The T cell Peripheral blood samples from 13 patients with IgG myeloma (eight IgG and five IgG) and urine from two patients with receptor ␤ probe used was a 0.4 kb fragment derived from a cDNA which includes the T cell receptor CT␤2 region of light chain disease (one and one ) were used to purify IgG and light chains, respectively. These 15 patients presented to chromosome 7. The immunoglobulin heavy chain gene probe used was a 5.4 kb cDNA fragment flanking the JH(J1-J6) the clinic on consecutive days and represent a cross-section of the original cohort (four were in progressive disease). IgG sequences on chromosome 14 (Oncogene Science, Uniondale, NY, USA). Each probe was labelled with ␣ 32 P dCTP was purified by affinity chromatography using DEAE Affi-Gel Blue (Bio-Rad Laboratories, Richmond, CA, USA). Normal IgG using a megaprime labelling system (Amersham). Only patients who had rearrangements detected using at least two was purified from a pool of eight normal sera, and an additional control was made from the serum of a patient with different restriction enzymes were considered to be rearranged. IgA myeloma. These preparations were dialysed against 1% ammonium carbonate and lyophilised. A portion of each lyophilised IgG was digested with 1% pepsin (Sigma, St Louis, MO, USA) in acetate buffer pH 5.0 overnight at 37°C and the Other studies F(ab′) 2 isolated by column chromatography on Sephadex G150 (Pharmacia, Uppsala, Sweden) using 1% ammonium carbonate to elute the fractions and which were lyophilised.
Serum immunoglobulin levels were determined on a Roche Light chains were purified from urine by precipitation in 75%
Cobas FARA analyser (Hoffman La Roche, Basel, Switzerland). saturated ammonium sulphate followed by dialysis in 1% M proteins were analysed by immunofixation (Silenus, Melammonium carbonate, column chromatography on Sephadex bourne, Australia) and serum ␤2-microglobulin was determ-G-150 and subsequent lyophilisation. The purity of these ined by radioimmunoassay (Pharmacia). Statistics were perforpreparations was checked by immunofixation on a Paragon med with SPPS and verified by the NH&MRC Clinical Trials Gel (Beckman Instruments, Brea, CA, USA).
Centre. Lyophilised immunoglobulin preparations were dissolved in phosphate-buffered saline at pH 7.2 (PBS) to give a 2 g/l solution, biotinylated with biotinamidocaproate-N-hydroxysuccinimide ester (Sigma) and then dialysed against PBS. 30 BiotinResults ylated immunoglobulin fragments were stored at 4°C in 0.1% sodium azide. In order to standardize the degree of bioIncidence of T cell receptor ␤ gene rearrangements in tinylation, these proteins were assayed in an ELISA system peripheral blood of patients with myeloma using microtitre plates with wells coated with the immunoglobulin fragments and then treated with streptavidin-HRP Using Southern blot technology, T cell receptor ␤ gene (Dakopatts, Carpinteria, CA, USA) before colour development rearrangements were detected in 38 peripheral blood samples with a substrate of o-phenylenediamine (Sigma) .
from patients with myeloma (32% of the total). The incidence of T cell rearrangements was lower in samples taken at diagnosis (25%; n = 35) and stable/plateau phase (23%; n = 39)
Identification of idiotype-reactive cells than in progressive disease (70%; n = 45). The increased incidence of rearrangements detected in progressive compared Buffy-coat cells from heparinized peripheral blood samples with stable disease was statistically significant ( 2 = 14.7; were washed in PBS and resuspended at 2 × 10 9 /l. Aliquots of P Ͻ 0.001). Figure 1 shows typical Southern blots after diges-100 l were incubated with 50 l of the biotinylated immunotion with EcoRI ( Figure 1a ) and HindIII (Figure 1b) . The mean globulin preparations for 30 min at room temperature. Red age of patients with T cell gene rearrangements (64 years) was cells were lysed and leucocytes were washed in PBS before not significantly different from those patients with a germline incubation with streptavidin-fluorescein conjugate (Dako) and T cell receptor configuration (63 years). There was no correanti-CD3-phycoerythrin (Becton Dickinson, San Jose, CA, lation between therapy and the presence of T cell gene USA) for 30 min at 4°C. Cells only, normal immunoglobulin rearrangements. Of the patients receiving alpha-interferon fragments and immunoglobulin fragments from other patients therapy, 28% had T cell gene rearrangements. This was not served as controls. Cells were analysed in a Coulter XL flow significantly different from the incidence of 32% found in the cytometer (Coulter, Hialeah, FL, USA) and the results were complete cohort of patients. expressed as a percentage of the population which colabelled for CD3 and F(ab′) 2 fragments.
Correlation between T cell receptor ␤ and B cell (JH) Southern blots rearrangements in the peripheral blood A buffy coat was prepared by Ficoll-Paque separation of 30 ml of heparinised peripheral blood. After lysis of red cells As an additional control, B cell clonality studies were performed on the same filters after allowing for 32 P decay. Of the with 1 mM MgCl 2 , DNA was extracted using equal parts of chloroform iso-amyl alcohol and tris-saturated phenol pH 8.0 38 samples which had evidence of T cell clonality, only nine (24%) also had detectable immunoglobulin heavy chain gene and then precipitated with ethanol. Three restriction enzymes, BamHI EcoRI and HindIII (Boehringer Mannheim, Mannheim, rearrangements. Thus there was no correlation between T and B cell clonality in these samples. Germany), were used to prepare DNA digests which were Kaplan-Meier survival curves of 12 patients with and 28 patients without T cell receptor ␤ gene rearrangements at diagnosis. rearrangements (n = 12) have died whereas those patients with a germline configuration at diagnosis (n = 28) had a median survival of 40 months ( 2 = 5.8; P Ͻ 0.01). When the median survival was compared for 30 patients studied during progressive disease (Figure 4 ), those patients with T cell receptor ␤ gene rearrangements detected at least once in progressive disease (n = 17) had a significantly better survival from the onset of progressive disease than patients who never had T cell receptor ␤ gene rearrangements (n = 13; median 44 vs 19 months; 2 = 8.7, P Ͻ 0.003). Survival of patients with and without rearrangements to six different peripheral blood samples from 33 patients. For 27 of these patients (82%) all repeat samples gave the same The overall survival of patients who had T cell receptor ␤ gene result as the original sample. Figure 5 illustrates results from rearrangements detected at any time (n = 34), was significantly a patient whose T cell receptor ␤ gene was studied on three better than the overall survival for patients who never had T occasions during progressive disease. The first sample in procell rearrangements detected (n = 49) and is shown in Figure 2 gressive disease was rearranged but rearrangements were not (median not yet achieved vs 45 months; 2 = 6.2, P Ͻ 0.01).
detected during the subsequent 9 months prior to death sug-A Cox regression analysis showed no interaction between T gesting that the disappearance of the expanded T cell clone cell receptor ␤ rearrangements and serum ␤-2 microglobulin was consistent with a poor prognosis. levels.
There were 35 patients whose T cell receptor ␤ genes were studied at diagnosis (Figure 3) . None of the patients with
Figure 4
Kaplan-Meier survival curves of patients who had (n = 17) or did not have (n = 13) T cell receptor ␤ gene rearrangements Figure 2 Kaplan-Meier survival curves of 34 patients with and 49 patients who have never had T cell receptor ␤ gene rearrangements. during progressive disease.
had peripheral blood T cell receptor ␤ gene rearrangements detected by Southern blot analysis ( Table 1) . The remaining 10 patients had germline T cell receptor ␤ genes and no idiotype-reactive T cells in samples collected concurrently. In patient No. 10 who was studied serially over a 2 year period, the T cell receptor ␤ gene was germline in four out of four samples and idiotype-reactive T cells were detected in only one out of six samples. Unfortunately T cell receptor ␤ gene rearrangement studies were not able to be performed on this single positive sample.
Discussion
The suggestion that patients with myeloma have the potential for T cell-mediated immunoregulation of their malignant
Figure 5
Longitudinal studies on a patient with IgA myeloma from diagnosis till death. The IgA levels reflect the progress of the disease.
clone is an attractive concept which has important impli-DNA studies were performed on three occasions during progressive cations for antitumour effector cells in vivo and could form disease. There was one sample with rearranged (R) T cell receptor ␤ the basis of novel therapeutic approaches. This study has genes early in progressive disease but two subsequent samples were shown that 32% of peripheral blood samples from patients germline (G).
with myeloma have a clonal T cell population in their peripheral blood which can be detected by the presence of a rearranged T cell receptor ␤ gene. In addition, it has been
Presence of idiotype-reactive T cells in peripheral blood
shown that these patients have a significantly better survival than patients with no detectable T cell clonality. The results from a subgroup of 30 patients with progressive disease sugTwo colour flow cytometry was used to determine the binding of immunoglobulin fragments to peripheral blood CD3
+ cells gest that this T cell antitumour response can provide a significant survival advantage even in patients with progressive disfrom patients with myeloma ( Figure 6 ). To determine the percent of idiotype-reactive T cells the binding of allogeneic fragease. Analysis of 40 patients studied at presentation suggests that the presence of T cell clones is a good prognostic factor ments to CD3 cells, including fragments made from normal sera, were used as a control for the binding of autologous which is independent of serum ␤2-microglobulin. There was an excellent correlation between the presence of idiotypefragments. The sensitivity of the method, as determined by the variability of the binding of allogeneic fragments was 1.5%.
reactive T cells and the presence of T cell receptor ␤ gene rearrangements detected by Southern blots. Longitudinal stud- Figure 6 illustrates typical binding of allogeneic and autologous F(ab′) 2 fragments where 1.1% of the CD3 cells bound ies suggested that the T cell status rarely changes during the course of the disease but for those individual patients who did allogeneic F(ab′) 2 fragments and 6.9% of the CD3 cells bound autologous F(ab′) 2 fragments. lose detectable T cell clonality there was evidence of a poor prognosis ( Figure 5 ). Five out of 15 patients had more T cells that reacted with autologous immunoglobulin fragments than allogeneic fragBy applying the immune network theory 27 to these observations, M protein in myeloma patients could stimulate the ments (Figure 7 ). Idiotype-reactive T cells comprised 13.1% of the total CD3 population in one patient. The remaining 10 production or anti-idiotype antibodies directed against either heavy of light chains. The extended network theory 28 postupatients had an average of 2.0% fewer T cells binding to autologous than allogeneic control immunoglobulin fragments.
lates the involvement of T cells bearing complementary structures in the regulation of idiotype expressing B cells and proAll five patients with idiotype-reactive T cells detected also
Figure 6
Two colour flow cytometry plots of the coexpression of allogeneic (a) and autologous (b) F(ab′) 2 fragments on CD3 cells.
Figure 7
The % of peripheral blood T cells specifically binding to autologous immunoglobulin fragments in each of the 15 patients studied. technique, these additional patients may not necessarily have a survival advantage. T cell clones might only exert a clinically significant immunomodulatory effect in vivo when the vides a theoretical basis for the existence of idiotype-reactive number of idiotype-reactive T cells present is above a thres-T cells in patients with myeloma. The prognostic significance hold. Thus any analysis using PCR to detect T cell clones at of T cell clones in patients with myeloma detected either by low concentrations might detect a greater number of patients gene rearrangements or the presence of idiotype-reactive T with T cell clones but the lower number of cells present may cells was unknown prior to the present study although elevnot confer the same survival advantage which has been ated endogenous interleukin-2 levels have been shown to be demonstrated in those patients with positive Southern blots. a good prognostic factor. 25 The higher incidence of T cell rearrangements in patients T cells normally recognise antigen-derived peptides generin progressive disease was intriguing. It was at first anticipated ated by professional antigen presenting cells at an MHC that the presence of antitumour effector cells would be found restricted site. In these studies we have extended the obserpredominantly during plateau phase. Other investigators, also vation made by several other groups that there is often weak believing this to be true, have only used samples from patients but specific binding of M protein to the autologous T cells in stable or plateau disease for their studies. 7, 8, 31 However, it of patients with myeloma.
5-9,14,15,31 It is unlikely that whole 110 kDa F(ab′) 2 fragments bind to the T cell receptor. Rather has been shown that the expansion of idiotype-reactive, acti-
